In Brief: Forest's Infasurf
Forest's Infasurf: Lung surfactant for prophylaxis and treatment of respiratory distress syndrome in premature infants is "approvable" as of July 25. Some chemistry and labeling issues remain to be resolved prior to approval, Forest says. FDA must also make a final determination on whether Infasurf is chemically different or clinically superior to Abbott's Survanta, which has market exclusivity from orphan drug protection. Infasurf is calf lung surfactant extract and Survanta is calf extract-derived. Forest believes the data in the NDA (submitted March 13) show that Infasurf is both chemically different and clinically superior to Survanta. At a meeting with analysts in February, Forest CEO Howard Solomon asserted that Infasurf is more effective, lasts longer, and requires less supplementary oxygen and fewer installations than Survanta or Glaxo Wellcome's Exosurf ("The Pink Sheet" Jan. 15, T&G-12)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth